CLAIMS

What is claimed is:


1. ~~A method of treating~~ Use of at least one selective Farnesoid X receptor (FXR) agonist obtained from *Antrodia cinnamomea (Antrodia camphorate)* in the manufacture of a medicament for the treatment of at least one disease or disorder in a subject in need thereof, wherein a therapeutically effective amount of an extract of the at least one selective FXR agonist is to be administered to the subject, and wherein the administration enhances or induces FXR mediated transcriptional response in the subject. ~~the method comprising:~~

~~administering to the subject a therapeutically effective amount of an extract comprising at least one selective Farnesoid X receptor (FXR) agonist obtained from *Antrodia cinnamomea (Antrodia camphorate),* and~~


~~enhancing or inducing FXR mediated transcriptional response in the subject.~~

2. The use~~method~~ of claim 1, wherein the at least one FXR agonist is a triterpenoid compound.

3. The use~~method~~ of claim 2, wherein the triterpenoid compound is:



(I) or



(II),

or salts, solvates, isomers, tautomers, or prodrugs thereof.

4. The use~~method~~ of claim 1, wherein the at least one disease or disorder is related to one selected from intestine, liver, kidney, and adrenal gland.

5. The use~~method~~ of claim 1, wherein the at least one disease or disorder is selected from a liver disease, obesity, diabetes, diarrhea, abdominal pain, hypertension, itchy skin, liver cancer, hepatitis, biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, inflammation, and fibrosis.

6. The use~~method~~ of claim 1, wherein the administration~~administering~~ induces about 60% to about 85% of FXR activity in the absence of chenodeoxycholic acid (CDCA).

7. The use~~method~~ of claim 1, wherein the administration~~administering~~ stimulates FXR activity by about 15% to about 30% in the presence of CDCA.

8. The use~~method~~ of claim 1, wherein the administration~~administering~~ has no impact or insignificant impact on any other hormone receptor signaling pathway in the subject.

9. The use~~method~~ of claim 1, wherein the administration~~administering~~ has no impact or insignificant impact on liver X receptor (LXR) mediated transcriptional response.


10. The use~~method~~ of claim 1, wherein the concentration of the triterpenoid is about 10 μM to 85 μM.

11. The use~~method~~ of claim 1, wherein the subject is a mammal.


12. The use~~method~~ of claim 11, wherein the subject is human.

13. Use of a composition comprising at least one FXR agonist selected from the group consisting of~~A method of treating an intestinal, liver, kidney, or adrenal gland disease or disorder in a subject in need thereof, the method comprising:~~

~~administering to the subject a therapeutically effective amount of a composition comprising at least one FXR agonist selected from the group consisting of~~




(I),




(II), and pharmaceutically acceptable salts, solvates, tautomers, or prodrugs thereof in the manufacture of a medicament for the treatment of an intestinal, liver, kidney, or adrenal gland disease or disorder in a subject in need thereof, wherein a therapeutically effective amount of the composition is to be administered to the subject.

14. The use~~method~~ of any one of claims 1 to 13, wherein the administration~~administering~~ is by a route selected from the group consisting of intravenous, subcutaneous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

15. A pharmaceutical composition comprising at least one FXR agonist selected from the group consisting of



(I),



(II),

and pharmaceutically acceptable salts, solvates, tautomers, or prodrugs thereof; and

at least one pharmaceutically acceptable excipient,

wherein the composition comprises about 0.0001% to about 1% w/w of at least one triterpenoid compound from *Antrodia cinnamomea* that is not (I) or (II).

16. The pharmaceutical composition of claim 15, wherein the composition comprises a core comprising the at least one FXR agonist coated by the at least one pharmaceutically acceptable excipient or a matrix comprising the at least one FXR agonist interspersed with the at least one pharmaceutically acceptable excipient.

17. ~~A method of treating at least one disease or disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount~~Use of the composition of claim 15 in the manufacture of a medicament for the treatment of at least one disease or disorder in a subject in need thereof, wherein a therapeutically effective amount of the composition is to be administered to the subject.

18. The use~~method~~ of claim 17, wherein the disease or disorder is selected from a liver disease, obesity, diabetes, diarrhea, abdominal pain, hypertension, itchy skin, liver cancer, hepatitis, biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, inflammation, and fibrosis.